Resultado da Busca
21 de fev. de 2021 · Brain metastases (BM) from colorectal cancer (CRC) are rare. There is little available information regarding incidence, risk factors, prognostic factors, treatment, and overall survival (OS). In this systematic review we performed a research of the current literature and exposed an average incidence of 2.10%.
- Brain metastasis from colorectal cancer: Treatment, survival ...
To investigate the clinical characteristics, survival,...
- Brain metastasis from colorectal cancer: Treatment, survival ...
22 de jan. de 2021 · Results: Among 75,901 patients with stage 4 colorectal adenocarcinoma, 1.6% had brain metastasis. Patients with brain metastasis were more likely to have bone (23% vs. 5%, p < 0.001) and lung metastasis (52% vs. 21%, p < 0.001), but less likely to have liver metastasis (56% vs. 72%, p < 0.001) compared to patients without brain ...
- Suleyman Yasin Goksu, Muhammad Shaalan Beg, Aravind Sanjeevaiah, Emrah Gumusgoz, David Hsieh, Muhamm...
- 2021
4 de fev. de 2020 · Brain metastasis (BM) from colorectal cancer is uncommon (0.6-1.36%). This study aims to investigate the patient characteristics, treatment modalities and prognostic factors in this rare population. Methods: 104 patients with brain metastasis disease from CRC were identified from over 30,000 colorectal cancer patients at the Mayo ...
- Zhaohui Jin, William Breen, Rui Jin, Paul D. Brown, Joleen Marie Hubbard
- 2020
- Incidence of BM in Patients Diagnosed with CRC
- Incidence of BM in Other CRC Populations
- Characteristics of Patients with Brain Metastases
- Timing of Brain Metastases
- Gender
- Stage of Primary Disease
- Rectal Location of Primary Tumor
- Metastatic Disease
- Chemotherapy Before BM Development
- Biomarkers
All 18 studies (Table 1 and Fig. 2) with patients diagnosed with CRC reported an incidence of BM between 0.6 and 2.9 % [7–24]. In the 16 studies eligible for pooling of data, the total number of CRC patients was 100,825 and the number of BM patients was 1588, resulting in an incidence of 1.55 % (95 % CI 1.48–1.63 %). The variation in the reported i...
Several studies reported an incidence from various CRC populations (Table 1), including three that also reported an incidence in all patients with CRC [9, 13, 24]. Nine studies reported an incidence of BM in a cohort of metastatic CRC (mCRC) patients. However, Hess et al. collected data, at a single time point, 4 months after referral of the patien...
The majority of the 59 studies reported clinicopathological characteristics of BM patients (Table 2), but only a few analyzed a statistical association. Of the 16 studies, eligible for pooling of data, only 14 described the characteristics of all included BM patients [7, 8, 10–16, 18–21, 23].
The median age at BM diagnosis ranged from 56 to 73 years. Four studies reported a median age higher than 65 years, and four studies reported it to be less than 60 years. In seven studies eligible for pooling of data, the age ranged between 55.7 and 73 years, and only two reported a median age higher than 65 years. Only seven studies reported that ...
Thirty-seven studies reported the gender of BM patients. In these studies, 39 to 80 % were male. In 14 studies eligible for pooling of data, between 44 and 80 % of BM patients were male and the weighted mean was 57.2 %. The only study that examined the association between gender and BM was Barnholtz-Sloan et al., who reported a borderline significa...
Twenty-six studies described the stage of primary tumor at diagnosis of CRC. In these studies between 8 and 64 % had stage 4 disease, most of the studies reporting more than 30 %. Generally stage 3 disease was the most common among BM patients in the included studies. In studies eligible for pooling of data, the weighted mean of patients having sta...
Totally, 31 studies reported that the frequency of rectal cancer among patient with BM ranged from 14 to 71 %. Most studies reported a frequency of 40 to 60 %. Thirteen studies were eligible for pooling of data, and in these, 20 to 67 % of BM patients had rectal primaries, with a weighted mean of 48.5 %. Both autopsy studies reported that 41 % of B...
Twenty-nine studies described the number of patients with extracranial metastases at diagnosis of BM. It ranged between 5 and 100 %. However, only one study reported 5 % , and all other reported a frequency higher than 63 %. Eleven of the studies eligible for pooling of data detailed how many of their BM patients had extracranial metastases, the in...
Eleven studies included information about chemotherapy before BM were diagnosed. The number of patients who received chemotherapy before BM were diagnosed ranged from 53 to 92 % in the studies [12, 16, 19, 21, 24, 25, 43, 47, 51, 52, 59]. Sundemeyer et al. showed that the incidence of BM increased as the number of treatment lines increased, but thi...
RAS were the most investigated DNA mutations associated with BM. Mostly only KRAS was investigated, but two studies also included NRAS mutation analysis [26, 31]. Yeager et al. performed RAS mutation analysis in 918 CRC patients, and showed that patients with NRAS and/or KRAS mutations had statistically significant higher incidence of BM (6.1 vs. 1...
Background: Brain metastases (BMs) from colorectal cancer (CRC) are unusual; however, an increase in incidence has been reported. The evidence available on the subject is scarce, and a better understanding is warranted.
Brain metastases (BM) from colorectal cancer (CRC) are a rare event. However, the implications for affected patients are severe, and the incidence has been reported to be increasing. For clinicians, knowledge about the characteristics associated with BM is important and could lead to earlier diagnosis and improved survival. Method:
